Figure 6.
Figure 6. Proliferation and IL-2 secretion in cotreatment conditions in wild-type and PKCθ–/– T cells. (A-B) Proliferative response and (C-D) IL-2 production of purified mature CD3+ T cells in the presence of inhibitors as specified. The panPKC LMWI reduces the proliferation of wild-type but not PKCθ–/– T cells significantly (P < .05), whereas the IL-2 production is significantly reduced in both genotypes. Cells were left unstimulated or were stimulated with anti-CD3 (precoated at a concentration of 10 μg mL–1) plus soluble anti-CD28 (1 μg mL–1) as indicated. Arrows mark the rescue result occurring in wild-type PKCθ+/+ (significantly in the IL-2 assay; P = .037) but not PKCθ–/– T cells. Results shown are the mean ± SD of at least 3 independent experiments.

Proliferation and IL-2 secretion in cotreatment conditions in wild-type and PKCθ–/– T cells. (A-B) Proliferative response and (C-D) IL-2 production of purified mature CD3+ T cells in the presence of inhibitors as specified. The panPKC LMWI reduces the proliferation of wild-type but not PKCθ–/– T cells significantly (P < .05), whereas the IL-2 production is significantly reduced in both genotypes. Cells were left unstimulated or were stimulated with anti-CD3 (precoated at a concentration of 10 μg mL–1) plus soluble anti-CD28 (1 μg mL–1) as indicated. Arrows mark the rescue result occurring in wild-type PKCθ+/+ (significantly in the IL-2 assay; P = .037) but not PKCθ–/– T cells. Results shown are the mean ± SD of at least 3 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal